ArticlePediatric cardiology2026
Long-term CMR Findings in Pediatric COVID-19 Related Myocarditis.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac magnetic resonance (CMR) is a key modality for diagnosing and monitoring myocarditis, including cases related to COVID-19 infection and Multisystem Inflammatory Syndrome in Children (MIS-C). While acute findings are often favorable, the persistence of abnormalities over time remains uncertain. This retrospective study included 21 pediatric patients with suspected COVID-19-related myocarditis between March 2020 and July 2023. All underwent CMR as part of clinical evaluation. Imaging findings were analyzed at early (< 30 days), mid (30-364 days), and long-term (≥ 365 days) intervals. Myocarditis was defined using the 2009 Lake Louise criteria. Of the 21 patients (mean age 13.1 years, 57% male), 8 had follow-up CMRs (median time to follow-up 347 days). Etiologies included MIS-C (57%), confirmed COVID-19 (19%), and suspected COVID-19 (24%). A total of 30 CMR studies were analyzed. Initial CMR met 2009 Lake Louise criteria in 8 patients (38%). Across temporally categorized studies, LGE declined from 46% of early studies to 25% of mid-term studies and was absent on long-term studies; pericardial effusions similarly declined from 46% to 25% to 0%. EGE remained frequent across timepoints (77%, 83%, and 80%, respectively). Among patients with serial CMR, no patient had edema on follow-up, LGE persisted in 1 of 8 (13%), pericardial effusion in 1 of 8 (13%), and only 1 of 8 (13%) continued to meet Lake Louise criteria. Biventricular systolic function remained normal on follow-up imaging. Initial LGE demonstrated marked lateral wall predominance (Cochran's Q = 13.38, p = 0.004). Median clinical follow-up was 20 months (IQR 11-38), with no documented arrhythmias, heart failure symptoms, cardiac-related rehospitalizations, or mortality. In pediatric myocarditis associated with COVID-19, most CMR abnormalities improve over time, with resolution of edema and substantial reduction in LGE and pericardial effusion. Persistent EGE remains common, although its clinical significance is uncertain. Medium-term clinical outcomes were favorable. Larger prospective studies are needed to define the long-term significance of persistent imaging abnormalities.
Indexed as
Identifiers
42313127What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.